If we continue covering GLP-1s for weight loss, our forecasts show these drugs will drive an unsustainable increase in the cost of medical coverage for everyonewhether they take the medication or not, read a press release from Blue Cross Blue Shield, which ended coverage January 1
CrossRef Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study Ki Wook Kim, Nayoung Kim, Yonghoon Choi, Won Seok Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Young Suk Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Gastric Cancer.2021
(Diane reported that compounded drugs are easily found legally in the US through many telehealth providers
In the GLP-1 sector, specific technical transfer challenges include: Peptide Chemistry Complexity: The multi-step SPPS processes have many critical points: resin type, activation reagents, deprotection kinetics
Patient-facing summaries like the FDAs Wegovy safety summary help set expectations, while the FDA prescribing information provides the fuller context on adverse reactions and why clinicians slow the titration when symptoms interfere with daily life
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg with semaglutide 2.4 mg